Solara Active Pharma Sciences, a prominent player in the Active Pharmaceutical Ingredients (APIs) sector, is currently capturing significant market attention. The company’s stock has demonstrated a remarkable upswing, gaining 34% over the past month. This surge reflects growing investor confidence in Solara’s ambitious strategic transformation.
Driving The Market Buzz
Solara is executing a profound strategic pivot, moving decisively away from lower-margin, non-regulated markets to concentrate on higher-value, regulated global markets. This strategic re-orientation has already seen regulated markets contribute a substantial 76% to the company’s total business. Concurrently, Solara is actively reducing its reliance on the plain Ibuprofen drug, instead prioritizing expansion in value-added Ibuprofen derivatives and a diversified portfolio of non-Ibuprofen products.
Solara’s Core Business Strengths
Solara Active Pharma Sciences specializes in the manufacture of APIs for a wide array of therapeutic areas. Its comprehensive product portfolio boasts over 60 commercial APIs, including key products in anti-inflammatory and anti-infective segments. The company is recognized as a major global supplier of Ibuprofen and also offers specialized Contract Research and Manufacturing Services (CRAMS) to other pharmaceutical companies, leveraging its expertise for their unique needs.
Unlocking Future Value: The CRAMS & Polymers Demerger
A cornerstone of Solara’s structural transformation is the planned demerger of its CRAMS and Polymers businesses into a new, independent entity to be named Synthix Global Pharma Solutions. This strategic carve-out is designed to unlock significant value and allow for focused growth. The new CRAMS entity, despite its current revenue of Rs 100 crores, holds substantial potential with its 1000 KL capacity. With its specialization in complex drug contract manufacturing, Synthix Global Pharma Solutions is poised for rapid expansion, with projections to triple or quadruple its turnover to approximately Rs 500 crores within the next 3-4 years.
FY25: A Year Of Reset And Resilience
The fiscal year 2025 proved operationally challenging for Solara, primarily due to headwinds faced in the Ibuprofen market. This led to the company missing its revenue and EBITDA guidance. However, management asserts a “strong comeback,” supported by tangible improvements in financial metrics. Between FY22 and FY25, Gross Margin expanded from 37.8% to 51.5%, and EBITDA Margin significantly improved from negative to 16.5%.
Strengthening The Balance Sheet
Solara is firmly committed to reinforcing its financial health through a proactive debt reduction strategy. Gross debt has been successfully reduced from Rs 1,000 crores in FY24 to Rs 776 crores. Further reduction to approximately Rs 650 crores is anticipated through proceeds from the recent rights issue. The demerger of the CRAMS & Polymers business is also expected to contribute by pushing down Rs 200 crores of debt. Solara’s ambitious financial target is to achieve a net debt/EBITDA of 1.7–1.8x by Q1 FY27, with the ultimate vision of becoming a debt-free entity.
Outlook For FY26
Looking ahead, Solara Active Pharma Sciences anticipates a strong performance for FY26. The company projects revenue growth of approximately 10% year-on-year and EBITDA growth in the range of 15–20% year-on-year. This positive outlook is expected to be driven by continued gross margin expansion and leveraging operational efficiencies, setting a clear trajectory for sustained profitability and growth
. Read more on Markets by NDTV Profit.